Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.575 USD | +0.59% | +14.96% | +11.47% |
Jun. 26 | Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program | MT |
Jun. 26 | Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares. | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Solutions
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -50.43% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Israel
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -50.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Joshua Hexter
COO | Chief Operating Officer | 53 | 13-04-13 |
Leonard Sank
BRD | Director/Board Member | 59 | 07-10-22 |
Zach Herschfus
IRC | Investor Relations Contact | - | - |
Netanel Derovan
LAW | General Counsel | - | 22-01-08 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Leonard Sank
BRD | Director/Board Member | 59 | 07-10-22 |
Arie Mayer
BRD | Director/Board Member | 67 | 19-12-04 |
Benjamin Shapiro
BRD | Director/Board Member | 40 | 23-04-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 40,628,924 | 35,961,754 ( 88.51 %) | 0 | 88.51 % |
Company contact information
Oramed Pharmaceuticals, Inc.
1185 Avenue of the Americas 3rd Floor
10036, New York
+844 967 2633
http://www.oramed.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.47% | 105M | |
+17.72% | 44.87B | |
-10.33% | 37.8B | |
+37.55% | 37.61B | |
+29.36% | 31.32B | |
-8.44% | 27.4B | |
+12.45% | 26.32B | |
+44.19% | 14.07B | |
+31.93% | 12.5B | |
-7.67% | 11.23B |
- Stock Market
- Equities
- ORMP Stock
- Company Oramed Pharmaceuticals Inc.